Clinical Trials Logo

Localized Resectable Tumor clinical trials

View clinical trials related to Localized Resectable Tumor.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04795661 Active, not recruiting - Clinical trials for MSI/dMMR or EBV-positive Gastric Cancers

Immunotherapy in MSI/dMMR Tumors in Perioperative Setting.

IMHOTEP
Start date: October 18, 2021
Phase: Phase 2
Study type: Interventional

This trial is a multicenter, 4-cohort, prospective, Phase II trial conducted in patients with untreated resectable MSI/dMMR carcinomas or EBV+ gastric cancer and aiming to evaluate the safety and the efficacy of ICI (immune checkpoint inhibitor) as neoadjuvant treatment in these patients. We hypothesize that immune checkpoint inhibitors (ICPi) will benefit to MSI/dMMR tumors from the early stages, whatever their anatomical origin. We assume that this neoadjuvant treatment would improve the response rate, providing even high rate of pathological complete responses and prolong patients survival. We anticipated endometrial, colorectal and gastric cancers to be the most frequent recruited and constructed our statistical hypothesis with results in those 3 cancers. However patients with other localized MSI/dMMR tumors could be included.